Navigation Links
pfuturbo DNA Polymerase:,,,A High-Performance, High-Fidelity Enzyme Ideal for PCR Cloning


Produce PCR amplicons that are easily cloned with high efficiency

pfuturbo DNA Polymerase:
A High-Performance, High-Fidelity Enzyme Ideal for PCR Cloning

Jeff Braman Holly Hogrefe
Stratagene

A chloramphenicol resistance (CAM) gene generated from pfuturbo DNA polymerase *, was cloned into the PCR-Script vector with greater than 85% efficiency. PfuTurbo DNA polymerase not only creates high-fidelity products, it also generates blunt-end PCR products, which eliminates the need for polishing. PfuTurbo DNA polymerase enhances PCR product yield without altering the fidelity of DNA replication, making it the enzyme of choice for reliable PCR product amplification and subsequent cloning.

Stratagene recently introduced PfuTurbo DNA polymerase,1 a special formulation of cloned Pfu DNA polymerase and a novel thermostable factor** that enhances PCR product yield without altering the fidelity of DNA replication. PfuTurbo DNA polymerase can be used to amplify complex genomic DNA targets up to 10 kb in length and vector targets up to 15 kb in length. It also amplifies complex targets in higher yield than Taq DNA polymerase or other commercially available proofreading PCR enzymes. Because Pfu DNA polymerase is known to generate blunt-end amplicons that can be easily cloned using the PCR Script cloning kit2 we assumed PfuTurbo DNA polymerase would also possess this characteristic.

Cloning blunt-end amplicons generated with enzymes such as PfuTurbo DNA polymerase is significantly more convenient than cloning amplicons produced with Taq DNA polymerase. Taq DNA polymerase creates amplicons with 3 overhangs.3,4 These molecules are cloned with low efficiency using the TA Cloning vector,2 or with high efficiency using the blunt-end PCR-Script vector, following treatment with Pfu DNA polymerase in the presence of deoxynucleoside triphosphates to polish the ends.2,5,6 Furthermore, PfuTurbo DNA polymerase has an error rate six-fold lower than that of Taq DNA polymerase,7 a crucial factor for accurate cloning.

Amplicon Generation

The CAM gene from plasmid pBC SK (+) was amplified with Stratagenes PfuTurbo and Taq2000 DNA polymerases. The CAM gene from plasmid pBC SK (+) was amplified with Stratagenes PfuTurbo and Taq2000 DNA polymerases. Reactions contained 100 ng pBC SK (+) DNA, 200 mM dNTPs, 1 mg of each CAM primer (primer 1-5 GCTGTGACGGAAGATCACTTCGC 3; primer 2-5 GCTCCACGGGGAGAGCCTGAGCA 3), the appropriate 1X buffer for each enzyme and either PfuTurbo DNA polymerase, Pfu DNA polymerase or Taq DNA polymerase and were performed in a RoboCycler Gradient 96 thermocycler.

Taq DNA polymerase is known to introduce an additional 3-A or 3-C nucleotide3,4 onto amplicons produced with primers used in this experiment. Therefore, the amplicon generated from Taq DNA polymerase was polished prior to blunt-end ligation to the PCR-Script vector. The PCR product was first purified using the StrataPrep PCR purification kit8 to remove Taq DNA polymerase, primers, PCR contaminants, and buffer components. For the polishing reaction, a 10-l portion of the purified amplicon was incubated at 72C for 30 minutes in 1X reaction buffer, 100 M dNTPs, and 0.5 unit of Pfu DNA polymerase. To stop the reaction, the tube was placed on ice. Another portion of the purified Taq-generated amplicon was not subjected to a polishing reaction and served as a control.

The amplicon generated by PfuTurbo DNA polymerase was also purified using the StrataPrep PCR kit method prior to the ligation reaction. The CAM amplicons were ligated to the PCR-Script vector, and the products were transformed into Epicurian Coli XL1-Blue MRF Kan supercompetent cells according to instructions in the PCR-Script Amp SK(+) cloning kit manual. The transformation mixtures were plated on LB ampicillin (50 g/ml) plates containing 0.5mM IPTG and 40 g/ml X-gal. Following overnight incubation at 37C, recombinant (white) and nonrecombinant (blue) colonies were counted. White colonies containing the putative insert were replica plated onto LB plates containing chloramphenicol (35 g/ml) to determine the percentage of CAM-resistant positives.

Figure 1

The mean percentage of recombinant clones per plate (white colony number divided by blue colony number multiplied by 100) and the mean percentage of white colonies that were also CAM-resistant are presented in Figure 1: PfuTurbo DNA polymerase produced CAM amplicons cloned with high efficiency (85%). Amplicons generated from Taq DNA polymerase were also cloned with greater than 85% efficiency, if the amplicons were polished prior to ligation to the PCR Script vector. The cloning efficiency of Taq-generated product was less than 10% in these experiments if no polishing reaction was performed (data not shown).

Conclusions

PfuTurbo DNA polymerase is a high-performance, high-fidelity enzyme formulation ideal for generating blunt-end PCR amplicons that are easily cloned with high efficiency using the PCR-Script cloning kit. Amplicons generated with Taq DNA polymerase not only require polishing prior to ligation to the PCR Script vector but also possess six-fold greater errors. When compared to Pfu DNA polymerase, PfuTurbo DNA polymerase allows the use of shorter extension times, fewer PCR cycles, and lower concentrations of DNA template.1 PfuTurbo DNA polymerase couples enhanced PCR performance and product yield with high-fidelity while eliminating the need for polishing, making it the enzyme of choice for fast, reliable, and accurate PCR cloning.

REFERENCES
  1. Hogrefe, et al. (1997) Strategies 10: 93-96.

  2. Sanchez, T., Zheng, C.-F., and Bauer, J. (1996) Strategies 9: 44-46.

  3. Clark, J.M. (1988) Nuc. Acids Res. 16: 9677-9686.

  4. Hu, G. (1993) DNA and Cell Biol. 12: 763-770.

  5. Costa, G. and Weiner, M.P. (1994) Strategies 7: 47-48.

  6. Pearson, S. and Bauer, J.C. (1996) Strategies 9: 26-27.

  7. Cline, J., Braman, J.C., and Hogrefe, H.H. (1996) Nuc. Acids Res. 24: 3546-3551.

  8. Braman, J. and Basehore, S. (1997) Strategies 10 (2): 84-86.

* U.S. Patent No. 5,545,552 and patents pending.
** Patents pending.


'"/>

Source:


Page: All 1 2 3 4

Related biology technology :

1. PCR Performance Comparisons Between pfuturbo and Taq DNA Polymerases
2. Optimizing pfuturbo DNA Polymerase Amplification Reactions with Perfect Match PCR Enhancer
3. prostar RT-PCR Systems for Robust High-Fidelity RNA Amplification
4. High-Fidelity PCR with a Novel Polymerase Mixture
5. The Best Enzyme for the Toughest PCR Challenges Improved with New Hot-Start Feature
6. Comparing Fidelity and Performance of Proofreading PCR Enzymes
7. Greater Amplification Specificity with New Hot Start PCR Enzyme
8. Enzyme Immunoassay for Studying Intracellular Levels of cAMP
9. Improve Amplification Specificity with Hot Start PCR Enzyme
10. Choice of RT-PCR Enzymes
11. Properties of PCR Enzymes
Post Your Comments:
(Date:12/6/2009)... Boehringer Ingelheim today announced results from the RE-COVER(TM) ... direct thrombin inhibitor (DTI),(2) compared to dose-adjusted warfarin ... the trial were presented at the 51st American ... online in the New England Journal of ... primary outcome of the trial, six month incidence ...
(Date:12/4/2009)... Alberta Centre for Advanced Micro Nano Technology Products ... seminar, , EDMONTON, Dec. 4 /PRNewswire/ - Today ... how technologies like nanotechnology, biomaterials and microfluidics can ... innovative healthcare products that help promote health and ...
(Date:12/3/2009)... Houston, LLC announced today that it has updated ... vertical sleeve gastrectomy , along with the ... sleeve gastrectomy procedure at the facility was performed by ... October 20, 2009. The patient is reported as doing ...
(Date:12/3/2009)... FRANCISCO, Dec. 3 VIA Pharmaceuticals, Inc. (Nasdaq: ... of compounds for the treatment of cardiovascular and metabolic ... patient visit in its Phase 2 FDG-PET clinical trial ... patients and was carried out at five sites in ...
Breaking Biology Technology:RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Alberta companies delivering new products to the health & medical marketplace 2JourneyLite of Houston Now Offering Sleeve Gastrectomy 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4
... ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ) a biopharmaceutical ... candidates for the treatment,of cancer and infectious diseases, ... officer, is scheduled to present at the 2007,Thomas ... at 1:30 p.m. Eastern Daylight Time. The conference ...
... - ... ... PDL BioPharma, Inc.,(PDL) (Nasdaq: PDLI ) today announced a ... of novel antibodies in,oncology and select immunological diseases, following a months-long,business ...
... Aug. 28 The American Chemical Society,(ACS) presented the ... prestigious 2007 Heroes of Chemistry award this week,at the ... new 100,percent renewable ingredient -- the first of its ... Tenn., by the DuPont Tate & Lyle Bio,Products joint ...
Other Biology Technology:ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference 2PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development 2PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development 3PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development 4PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development 5DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM) 2DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM) 3DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM) 4
(Date:12/3/2009)... A coating on windows or solar panels that repels ... next electric car? New Tel Aviv University research, just ... in assembling peptides at the nano-scale level that could ... few years. , Operating in the range of 100 ...
(Date:12/3/2009)... in warmer water, according to an intriguing new study suggesting ... Experiments with two species of young damselfish on Australia,s Great ... reef fish are either consistently timid, or consistently bold, and ... temperatures rise. , A slight lift of just one or ...
(Date:12/3/2009)... scientists from the U.S. Department of Energy,s (DOE) Brookhaven ... Science has made a major step in understanding how ... necessary to carry out important biological processes. The research, ... Nature Structural & Molecular Biology , confirms that many ...
Breaking Biology News(10 mins):A window that washes itself? 2Fish with attitude: Some like it hot 2Grooving down the helix 2Grooving down the helix 3Managed Health Services Partners With Milwaukee Health Services to Increase Access to Care for Underserved Communities 48218 1Managed Health Services Partners With Milwaukee Health Services to Increase Access to Care for Underserved Communities 48218 2Managed Health Services Partners With Milwaukee Health Services to Increase Access to Care for Underserved Communities 48218 3PHOENIX AHF Magic Johnson HIV Testing Caravan 26 Southwest Center for HIV AIDS to Host Free HIV Testing Event at Off Chute Too 48214 1PHOENIX AHF Magic Johnson HIV Testing Caravan 26 Southwest Center for HIV AIDS to Host Free HIV Testing Event at Off Chute Too 48214 2PHOENIX AHF Magic Johnson HIV Testing Caravan 26 Southwest Center for HIV AIDS to Host Free HIV Testing Event at Off Chute Too 48214 3PHOENIX AHF Magic Johnson HIV Testing Caravan 26 Southwest Center for HIV AIDS to Host Free HIV Testing Event at Off Chute Too 48214 4PHOENIX AHF Magic Johnson HIV Testing Caravan 26 Southwest Center for HIV AIDS to Host Free HIV Testing Event at Off Chute Too 48214 5PHOENIX AHF Magic Johnson HIV Testing Caravan 26 Southwest Center for HIV AIDS to Host Free HIV Testing Event at Off Chute Too 48214 6Caliper Life Sciences to Webcast Investor Session of Open House 12528 1Caliper Life Sciences to Webcast Investor Session of Open House 12528 2
... in his lab. Millions of people the world over ... that has yet provided a universally accepted solution. However, a ... has come up with a practical weight loss solution for ... , For this development, Yaniv Linde, a 32-year-old Ph.D. ...
... of the University of Pennsylvania have found that deleting a ... loss of stem cell reservoirs in adult mice. This gene, ... and mutations in proteins in the DNA damage response underlie ... work appears in the inaugural issue of Cell Stem Cell. ...
... N.Y. – Cold Spring Harbor Laboratory (CSHL) researchers led ... Hughes Medical Investigator (HHMI) Greg Hannon have identified a ... tumor suppressor network, called the p53 pathway, to fight ... on several fronts to understand the p53 pathway because ...
Other Biology News:How to lose weight and not go hungry: HU researcher develops drug that mimics feeling of 'fullness' 2Loss of stem cells correlates with premature aging in animal study 2Study shows big power of small RNAs, not just proteins, in halting cancer 2
... 2 Detection System combines the indirect ... principle and Signets unique formulation of ... and reliablility. Signet reagents will achieve ... and automated protocols. ,Signets USA ...
Each bottle contains: Bromophenol Blue 0.25% w/v , Xylene Cyanol FF 0.25%, Glycerol solution 30% w/v...
XEDAR Antibody...
Rabbit Anti-JNK1/SAPK pan, Polyclonal Antibody...
Biology Products: